cmAngio® vs Study Watch
AI Verdict
Choose cmAngio® if…
Choose cmAngio® if your clinical practice aims to integrate cardiovascular risk assessment into routine mammography screenings for women. This AI-powered software detects Breast Arterial Calcifications (BAC) on both FFDM and DBT exams, providing valuable insights into cardiovascular health without additional radiation or procedures. It is ideal for enhancing early risk assessment within radiology and OB/GYN workflows.
View cmAngio® →Choose Study Watch if…
Choose Verily Study Watch if your clinical research requires continuous, non-invasive physiological monitoring of participants over extended periods. This prescription-only wearable collects multi-modal data, including ECG, heart rate, and movement, making it suitable for studies in cardiology, neurology, or sleep medicine. It is designed for researchers needing robust, long-term data collection for analysis within a secure cloud platform.
View Study Watch →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | cmAngio® | Study Watch |
|---|---|---|
| Pricing | Paid, out-of-pocket | Unknown |
| Deployment | Cloud-based, integrates with any DICOM-compliant viewer | The Study Watch is a wrist-worn, multi-sensor wearable device used for data collection in clinical trials. Data from the watch is encrypted and sent securely to the Verily Cloud using a USB syncing and charging cradle and a wireless connectivity bridge (Verily Study Hub). |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
cmAngio®cmAngiou00ae is designed for seamless integration into existing radiology workflows, emphasizing quick installation and compatibility with standard DICOM viewers. Its output is presented on a scorecard, making it easy for radiologists to interpret and incorporate into their practice. Study Watch, while user-friendly for patients to wear, requires a prescription and is primarily for clinical research, implying a more complex setup and data interpretation process for researchers.
Clinical Value
cmAngio®cmAngiou00ae offers immediate, FDA-cleared clinical value by detecting Breast Arterial Calcifications on mammograms to aid in early cardiovascular risk assessment without additional procedures. Study Watch, while collecting valuable physiological data like ECG and heart rate, is primarily positioned for clinical research. Its direct clinical application in routine patient care is less explicit compared to cmAngiou00ae's defined role in risk assessment.
Pricing & Value
TieBoth tools lack publicly available pricing information, making a direct comparison of their value propositions impossible. While cmAngiou00ae mentions potential limited-time offers for no-cost implementation, this does not provide a clear, long-term pricing structure. Study Watch's pricing is also not public, being tied to clinical research and partnerships.
Enterprise Readiness
cmAngio®Both tools are FDA-cleared, cloud-based, and claim HIPAA compliance. However, Verily's Study Watch faces an ongoing lawsuit alleging HIPAA violations and BAA breaches, which, despite denials, introduces a significant risk factor for enterprise adoption and trust. cmAngiou00ae, while requiring contact for BAA details, does not have such public legal challenges, suggesting a potentially smoother path for enterprise integration.
Innovation
TieBoth tools demonstrate significant innovation in their respective domains. cmAngiou00ae innovates by applying AI to existing mammography data to extract novel cardiovascular risk insights. Study Watch innovates with its multi-sensor wearable technology for continuous physiological monitoring, pushing the boundaries of remote data collection for clinical research.
Support & Docs
TieNeither the provided structured facts nor web searches yield sufficient public information to differentiate the two tools regarding the depth of their support services or the comprehensiveness of their documentation. Both companies generally mention customer or technical support, but specific details like SLAs or publicly accessible documentation portals are not readily available for either product.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | cmAngio® | Study Watch |
|---|---|---|
| Name | cmAngiou00ae | Study Watch |
| Primary Function/Purpose | FDA-cleared AI software for detecting Breast Arterial Calcifications (BAC) on mammograms, providing insights into cardiovascular health and aiding early risk assessment. | Prescription-only, sensor-based wearable device for non-invasive, continuous physiological monitoring in clinical research, collecting data like ECG, heart rate, and movement for analysis in Verily's cloud platform. |
| Categories | Cardiology AI, OB/GYN AI, Radiology & Imaging AI | Cardiology AI, Wearables & Remote Monitoring (RPM) |
| Specialties | Cardiology, Obstetrics & Gynecology, Radiology | Cardiology, Neurology, Sleep Medicine |
| Key Feature (Monitoring/Detection) | AI-based detection of Breast Arterial Calcifications (BAC) | Continuous physiological monitoring (ECG, heart rate, electrodermal activity, inertial movements) |
| Key Feature (Output/Processing) | Provides visualization of BAC location on a scorecard | Cloud-based data processing with algorithms and machine learning |
Videos
Demos, reviews, and walkthroughs featuring cmAngio® and Study Watch.
Frequently Asked Questions
More Comparisons
More matchups featuring cmAngio® or Study Watch
Backers
Who funded each tool's parent company.